Related references
Note: Only part of the references are listed.KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab
H. Bando et al.
BRITISH JOURNAL OF CANCER (2011)
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
N. Knijn et al.
BRITISH JOURNAL OF CANCER (2011)
KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications
Antoine Italiano et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
K. -L. Garm Spindler et al.
ANNALS OF ONCOLOGY (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy
Marie-Christine Etienne-Grimaldi et al.
CLINICAL CANCER RESEARCH (2008)
Association of k-ras mutational status and clinical outcomes in patients with metastatic colorectal. cancer receiving panitumumab alone
Daniel J. Freeman et al.
CLINICAL COLORECTAL CANCER (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
Daniele Santini et al.
ONCOLOGIST (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations
Sang Soo Hah et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2007)
Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics
Shantanu Sharma et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes
Jean-Christophe Weber et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells
MJ Silva et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2005)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status
C Oliveira et al.
HUMAN MOLECULAR GENETICS (2004)
Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas
P Zauber et al.
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY (2003)
Share Paper
